Home
overview

With the proliferation of chronic lung conditions, pharmaceutical companies and research institutions need to continuously find new innovative therapeutic solutions. Inseparable from the issues concerning Asthma, the problems associated with Chronic Obstructive Pulmonary Disease (COPD) are striking. These diseases combined, form one of the biggest potential killers in the coming decades.

SMi’s Asthma & COPD II Conference will uncover the latest developments in clinical research and uncover new advances delivery technologies. Special emphasis will be given to problems being faced in a global market, the acceleration of new drug concepts, the similarities and differences in the two diseases, as well as the various drug classes assigned to combat progressive symptoms.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Steven Kesten

Dr Steven Kesten, Therapeutic Area Director, Respiratory, Clinical & Scientific Affairs, Boehringer-Ingelheim

9:10 REGULATORY GUIDELINES

Dr John Warren

Dr John Warren, Medical Assessor, Medicines & Healthcare products Regulatory Agency (MHRA)

  • Current status
  • Guidelines for asthma
  • Guidelines for COPD
  • 9:50 IMPROVING EFFICIENCY IN THE DEVELOPMENT OF INHALED DRUGS

    Mark Egerton

    Mark Egerton, Chief Executive Officer, Pharmaceutical Profiles Ltd

  • Smart selection of formulation, device and inhalation route
  • Streamlining drug development timelines through integrated study design
  • Approaches in the evaluation of inhaled drug delivery: right place, right time, right level?
  • Better delivery, better patient compliance – case studies
  • 10:30 Morning Coffee

    10:50 DEVELOPMENT OF A NOVEL SMALL MOLCULE ANTAGONIST FOR INFLAMMATION AND ATOPY

    Dr Kevin Bacon

    Dr Kevin Bacon, Founder, Chief Scientific Officer, & Head, Research & Development, Actimis

  • Novel target validation and the discovery of suitable small molecule antagonists
  • Actimis Pharmaceutical’s novel anti-inflammatory compound
  • Pharmacological efficacy and preclinical development overview
  • 11:30 LONG-ACTING ANTICHOLINERGIC AGENTS

    Dr Craig Conoscenti

    Dr Craig Conoscenti, Senior Associate Director, Respiratory, Clinical & Scientific Affairs , Boehringer-Ingelheim

  • Bronchodilators and anticholinergics are the mainstays of COPD treatment
  • Abnormal inflammatory response in the lung
  • Cholinergic bronchoconstriction plays a significant role in the severity of COPD symptoms
  • Anticholinergic agents antagonise the airway bronchoconstrictive action of acetylcholine
  • Inhaled bronchodilators alleviate symptoms, improve airflow and decrease hyperinflation
  • 12:10 THE LABA ASTHMA DEBATE

    Dzelal Serdarevic

    Dzelal Serdarevic, Director, A&R Therapeutic Area, Clinical R&D, , Pfizer Ltd

  • Review of risk/benefit and positioning of LABA in asthma management
  • The salmeterol SMART study and response by regulatory authorities
  • The potential impact on positioning of LABA in asthma management
  • 12:50 Networking Lunch

    14:20 ADAPTATION OF ASTHMA MODELS TO MEET PRECLINICAL NEEDS

    Alison Kerr

    Alison Kerr, Director, Respiratory Inflammations, MD Biosciences

  • Current preclinical asthma models
  • Development of more rapid/sensitive readouts
  • Visualisation of the immune response as it occurs in asthma
  • Identification of mode of action in situ and in real time
  • 15:00 PROTEASE INHIBITORS IN THE TREATMENT OF COPD AND CF

    Malinda Longphre

    Malinda Longphre, Medical Science Liaison & Head, Medical Affairs, Aerovance Inc

  • Human clinical studies with protease inhibitors
  • 15:40 Afternoon Tea

    16:00 PHASE IV: REACHING THE PATIENT

    Dr Alan Davies

    Dr Alan Davies, European Medical Director, Kendle

  • Meeting international regulations
  • Getting the right patients into the right studies
  • Efficacy and safety
  • Other strategies for late phase studies
  • Reducing long-term side-effects and introducing prompt counter-measures
  • 16:40 LUNG FUNCTION PARAMETERS

    Aleck Harrison

    Aleck Harrison, Consultant Clinical Scientist, AJH Partners

  • Measuring lung functions and the relevant parameters differentiating asthma and COPD
  • Variables influencing LFTs
  • Identifying abnormalities and deducing their causes
  • The value of centralised spirometry over-reading
  • Case studies
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Noel Snell

    Dr Noel Snell, Global Medical Science Director, Emerging Respiratory Projects, AstraZeneca

    9:10 COMPARATIVE PATHOPHYSIOLOGY OF ASTHMA AND COPD

    Dr Noel Snell

    Dr Noel Snell, Global Medical Science Director, Emerging Respiratory Projects, AstraZeneca

  • Asthma and COPD – similarities and differences
  • Asthma – pathophysiology and potential therapeutic targets
  • COPD – pathophysiology and potential therapeutic targets
  • ‘Excluded’ trial subjects in obstructive lung disease – are we missing something important?
  • 9:50 PHOSPHODIESTERASE-4 INHIBITORS

    Dr Dirk Bredenbroeker

    Dr Dirk Bredenbroeker, Head, Clinical Research, Pulmonology, ALTANA Pharma

  • PDE4 as an important target for the development of anti-inflammatory therapy for airway disease
  • Mechanism of action in preclinical models
  • Efficacy and safety of PDE4 inhibitors under development - how might they change future treatment algorithms for asthma and COPD?
  • Profile of Roflumilast as a PDE4 inhibitor in late phase III development
  • 10:30 Morning Coffee

    11:00 BIOLOGICALS IN THE TREATMENT OF ASTHMA AND COPD

    Dr Rozsa Schlenker-Herceg

    Dr Rozsa Schlenker-Herceg, Senior Director, General Medicine, Pulmonary Division, Centocor

  • Targeting IgE and TNFa
  • Review of the clinical data available to date
  • Strong scientific rationale, no clinical efficacy
  • Anti-TNFa in COPD
  • 11:40 IMMUNE SYSTEM TARGETS IN THE TREATMENT OF ASTHMA

    Dr David Valacer

    Dr David Valacer, Senior Medical Director, Genentech Inc

  • Update on clinical experiences with Xolair®
  • Update on the immunomodulatory effects of long term Xolair® therapy
  • Review advances in the understanding of the role of T- cells in asthma pathophysiology
  • Describe the potential benefits and risks of targeting T- cells as a new therapeutic approach for asthma
  • Case study: Daclizumab (Zenapax®)
  • 12:20 Networking Lunch

    13:50 ANTI-INFLAMMATORY CORTICOSTEROIDS IN ASTHMA AND COPD

    Professor Malcolm Johnson

    Professor Malcolm Johnson, Global Director, Respiratory Science, GlaxoSmithKline

  • Characteristics of an ideal inhaled corticosteroid
  • Pharmacological attributes predicting topical efficacy and systemic safety
  • Corticosteroid sensitivity and sub-sensitivity
  • Current research and development
  • 14:30 INHALER DEVICES FOR PULMONARY DELIVERY

    Dr Peter  Scholes

    Dr Peter Scholes, Manager, Early Pharmaceutics & Technology, Drug Delivery Systems Division, 3M Healthcare

  • Inhalation market trends and impact on device selection
  • Understanding patient, clinical, industry and regulatory requirements
  • How can current/future device technology meet these needs?
  • What is required for success in the future marketplace?
  • 15:10 Afternoon Tea

    15:40 PATIENTS' ATTITUDES TO INHALATION THERAPY

  • Practical aspects of inhaled therapy
  • Factors that contribute to poor compliance in inhaled therapy
  • Lessons learned in delivering value to patients
  • Keith Allan

    Keith Allan, Head, Global Product Advocacy, Novartis

    Monica  Fletcher

    Monica Fletcher, Chief Executive Officer, Education for Health

    16:20 DEVELOPMENTS IN DRY POWDER INHALERS

    David Whitaker

    David Whitaker, Consultant, PA Consulting Group

  • What are the drivers for DPI development
  • What is coming next?
  • Emerging device overview
  • What might the future hold?
  • Will electronic devices ever be commercially viable?
  • Can Asthma and COPD benefit from more advanced platforms?
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    +

    Thistle Victoria

    Buckingham Palace Road
    London SW1W 0SJ
    United Kingdom

    Thistle Victoria

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.